DUBLIN, Ireland, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that Sarah Noonberg, MD, PhD, has decided to resign
DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan arenas, today announced that members of its senior
Clinical development programs advancing toward key milestones Dr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNP Novel discovery pipeline in neuroscience and orphan disease areas; highlights include tau and ALECT2 R&D Day hosted
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1 million, provides funding to advance diverse pipeline Presented new research at HFSA Annual
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that members of its senior management team will
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the third quarter and first nine
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) study Observed clinical efficacy and reductions in markers of inflammation were insufficient to advance PRX003 into mid-stage clinical development DUBLIN,
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP Response and Health-related Quality of Life Data Presented at Heart Failure Society of America Annual Meeting
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related Quality of Life DUBLIN, Ireland, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8 million, provides funding to advance diverse pipeline Initiated, with Roche, the global Phase 2
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, will announce financial results for the second quarter and first six
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson's disease Prothena to receive $30 million milestone payment under collaboration agreement with Roche DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today the appointment of Wagner Zago, PhD, as Chief
